Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (Copd); implications for stratified medicine?

Muscle and Nerve

Volumn 48, Issue 4, 2013, Pages 488-497

  Natanek, Samantha A ^a,b,c   Gosker, Harry R ^c   Slot, Ilse G M ^c   Marsh, Gemma S ^a   Hopkinson, Nicholas S ^a   Man, William D C ^a   Tal Singer, Ruth ^d   Moxham, John ^e   Kemp, Paul R ^b   Schols, Annemie M W J ^c   Polkey, Michael I ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

Author keywords

COPD; Fiber atrophy; Fiber shift; Muscle biopsy; Muscle histology; Quadriceps

Indexed keywords

AGED; ARTERIAL OXYGEN TENSION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EXERCISE; EXERCISE TOLERANCE; FAT FREE MASS; FEMALE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE DISEASE; PERCUTANEOUS BIOPSY; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; AGE; COMPARATIVE STUDY; EXERCISE TEST; FIBER ATROPHY; FIBER SHIFT; GENETIC MARKER; METABOLISM; MIDDLE AGED; MUSCLE HISTOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SKELETAL MUSCLE;

COPD; FIBER ATROPHY; FIBER SHIFT; MUSCLE BIOPSY; MUSCLE HISTOLOGY; QUADRICEPS;

AGE FACTORS; AGED; EXERCISE TEST; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUADRICEPS MUSCLE; SEVERITY OF ILLNESS INDEX;

GENETIC MARKER;

EID: 84891550400     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23784     Document Type: Article

References (57)

1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-1259.
2. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007;62:115-120.
3. Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809-813.
4. Shrikrishna D, Hopkinson NS. Chronic obstructive pulmonary disease: consequences beyond the lung. Clin Med 2012;12:71-74.
5. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;355:362-368.
6. Dodd JW, Marns PL, Clark AL, Ingram KA, Fowler RP, Canavan JL, et al. The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation. COPD 2012;9:390-394.
7. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 2000;109:207-212.
8. Seymour JM, Moore L, Jolley CJ, Ward K, Creasey J, Steier JS, et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax 2010;65:423-428.
9. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:629-634.
10. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J 1990;3:192-196.
11. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010;36:81-88.
12. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012;40:1115-1122.
13. Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007;62:944-949.
14. Gosker HR, Engelen MP, van Mameren H, van Dijk PJ, van der Vusse GJ, Wouters EF, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002;76:113-119.
15. Whittom F, Jobin J, Simard PM, Leblanc P, Simard C, Bernard S, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998;30:1467-1474.
16. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-1156.
17. Steiner MC, Barton RL, Singh SJ, Morgan MD. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J 2002;19:626-631.
18. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008;134:405-415.
19. Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010;109:635-642.
20. Steiner MC, Roubenoff R, Tal-Singer R, Polkey MI. Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review. Thorax 2012;67:1102-1109.
21. Saey D, Michaud A, Couillard A, Cote CH, Mador MJ, LeBlanc P, et al. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1109-1115.
22. Torres SH, Montes de Oca M, Loeb E, Mata A, Hernandez N. Gender and skeletal muscle characteristics in subjects with chronic obstructive pulmonary disease. Respir Med 2011;105:88-94.
23. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
25. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511-522.
26. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-735.
27. Pitta F, Troosters T, Spruit MA, Decramer M, Gosselink R. Activity monitoring for assessment of physical activities in daily life in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2005;86:1979-1985.
28. Edwards RH, Young A, Hosking GP, Jones DA. Human skeletal muscle function: description of tests and normal values. Clin Sci Mol Med 1977;52:283-290.
29. Polkey MI, Kyroussis D, Hamnegard CH, Mills GH, Green M, Moxham J. Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man. Muscle Nerve 1996;19:549-555.
30. Swallow EB, Gosker HR, Ward KA, Moore AJ, Dayer MJ, Hopkinson NS, et al. A novel technique for nonvolitional assessment of quadriceps muscle endurance in humans. J Appl Physiol 2007;103:739-746.
31. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
32. Hopkinson NS, Man WD, Dayer MJ, Ross ET, Nickol AH, Hart N, et al. Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease. Eur Respir J 2004;24:137-142.
33. Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 1975;35:609-616.
34. Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, van Loon LJ. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab 2007;292:E151-E157.
35. Russell AP, Wadley G, Hesselink MK, Schaart G, Lo S, Leger B, et al. UCP3 protein expression is lower in type I, IIa and IIx muscle fiber types of endurance-trained compared to untrained subjects. Pflugers Arch 2003;445:563-569.
36. Shultz EK, Willard KE, Rich SS, Connelly DP, Critchfield GC. Improved reference-interval estimation. Clin Chem 1985;31:1974-1978.
37. Miller AE, MacDougall JD, Tarnopolsky MA, Sale DG. Gender differences in strength and muscle fiber characteristics. Eur J Appl Physiol Occup Physiol 1993;66:254-262.
38. Gosker HR, Hesselink MK, Duimel H, Ward KA, Schols AM. Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J 2007;30:73-79.
39. Coronell C, Orozco-Levi M, Mendez R, Ramirez-Sarmiento A, Galdiz JB, Gea J. Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J 2004;24:129-136.
40. Testelmans D, Crul T, Maes K, Agten A, Crombach M, Decramer M, et al. Atrophy and hypertrophy signalling in the diaphragm of patients with COPD. Eur Respir J;35:549-556.
41. Stubbings AK, Moore AJ, Dusmet M, Goldstraw P, West TG, Polkey MI, et al. Physiological properties of human diaphragm muscle fibres and the effect of chronic obstructive pulmonary disease. J Physiol 2008;586:2637-2650.
42. Vogiatzis I, Simoes DC, Stratakos G, Kourepini E, Terzis G, Manta P, et al. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J;36:301-310.
43. Hayot M, Michaud A, Koechlin C, Caron MA, Leblanc P, Prefaut C, et al. Skeletal muscle microbiopsy: a validation study of a minimally invasive technique. Eur Respir J 2005;25:431-440.
44. Sala E, Roca J, Marrades RM, Alonso J, Gonzalez De Suso JM, Moreno A, et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1726-1734.
45. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax 2012;67:26-34.
46. Li X, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010;59:579-585.
47. Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med 2010;104:849-857.
48. Steiner MC, Evans R, Deacon SJ, Singh SJ, Patel P, Fox J, et al. Adenine nucleotide loss in the skeletal muscles during exercise in chronic obstructive pulmonary disease. Thorax 2005;60:932-936.
49. Halkjaer-Kristensen J, Ingemann-Hansen T. Variations in single fibre areas and fibre composition in needle biopsies from the human quadriceps muscle. Scand J Clin Lab Invest 1981;41:391-395.
50. Vecchi S, Belleudi V, Amato L, Davoli M, Perucci CA. Does direction of results of abstracts submitted to scientific conferences on drug addiction predict full publication? BMC Med Res Methodol 2009;9:23.
51. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev 2007:MR000005.
52. Nikolic M, Malnar-Dragojevic D, Bobinac D, Bajek S, Jerkovic R, Soic-Vranic T. Age-related skeletal muscle atrophy in humans: an immunohistochemical and morphometric study. Coll Antropol 2001;25:545-553.
53. Simoneau JA, Bouchard C. Genetic determinism of fiber type proportion in human skeletal muscle. FASEB J 1995;9:1091-1095.
54. Akhmetov, II, Astratenkova IV, Druzhevskaia AM, Komkova AI, Liubaeva EV, Tarakin PP, et al. [The association of gene polymorphisms with the muscle fiber type composition]. Ross Fiziol Zh Im I M Sechenova 2006;92:883-888.
55. Hopkinson NS, Eleftheriou KI, Payne J, Nickol AH, Hawe E, Moxham J, et al. +9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2006;83:912-917.
56. Hopkinson NS, Nickol AH, Payne J, Hawe E, Man WD, Moxham J, et al. Angiotensin converting enzyme genotype and strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:395-399.
57. Hopkinson NS, Li KW, Kehoe A, Humphries SE, Roughton M, Moxham J, et al. Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. Am J Clin Nutr 2008;87:385-390.